Q1-Q3 2024: MONO’1 & MONO’2 - Development and Testing
Complete development of AI-driven health monitoring devices; CLM and
CGM. Conduct rigorous testing and validation of prototypes. Iterate
based on user feedback to enhance usability and functionality.
Q4 2024: MONO’1 CLM - Regulatory Clearance
Initiate FDA clearance process for CLM device. Ensure compliance
with regulatory standards and requirements. Begin preparations for
CGM device clearance.
Q1 2025: MONO’1 CLM - Market Entry and Launch
Secure FDA clearance for CLM device. Launch Medixbot's products in
the market. Focus on initial customer acquisition and user
engagement.
Q2-Q4 2025: MONO’1 CLM - Early Growth and Expansion
Scale marketing efforts to reach a wider audience. Establish
strategic partnerships with healthcare providers and institutions.
Expand product features based on user insights and market demand.
Beyond 2025: MONO’1 CLM - Scaling Operations
Scale production and distribution to meet growing demand. Enhance
customer support and service capabilities. Explore opportunities for
international expansion and partnerships.
Beyond 2025: MONO’1 CGM - Regulatory Clearance
Initiate FDA clearance process for CGM device. Ensure compliance
with regulatory standards and requirements. Begin preparations for
CGM device clearance.